IGC Pharma (IGC) Change in Receivables (2010 - 2025)
IGC Pharma (IGC) posted quarterly Change in Receivables of -$46000.0 for Q3 2025, down 387.5% year-over-year from $16000.0 in Q3 2024, and down 186.79% quarter-over-quarter from $53000.0 in Q2 2025.
IGC Pharma (IGC) Change in Receivables (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Change in Receivables for 16 consecutive years, with -$46000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Change in Receivables fell 387.5% year-over-year to -$46000.0; the TTM figure through Sep 2025 stood at $10000.0 (changed N/A YoY), while the FY2026 annual figure was $24000.0, up 200.0% from the prior year.
- Change in Receivables fell to -$46000.0 in Q3 2025 per IGC's latest filing, from $53000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $118000.0 in Q2 2023 and bottomed at -$132000.0 in Q1 2023.
- Historically, Change in Receivables has averaged -$3473.7 across 5 years, with a median of -$2000.0 in 2025.
- On a YoY basis, Change in Receivables climbed as much as 581.82% in 2025 and fell as far as 387.5% in 2025.
- IGC Pharma's Change in Receivables stood at $25000.0 in 2021, then surged by 148.0% to $62000.0 in 2022, then tumbled by 170.97% to -$44000.0 in 2023, then surged by 111.36% to $5000.0 in 2024, then slumped by 1020.0% to -$46000.0 in 2025.
- Business Quant data shows IGC's Change in Receivables at -$46000.0 in Q3 2025, $53000.0 in Q2 2025, and -$2000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | - |
| 10 | IGC Pharma | 30.43 Mn | 30.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -46,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | -2,000.00 |
| Mar 31, 2025 | -2,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Mar 31, 2024 | 39,000.00 |
| Mar 31, 2024 | 39,000.00 |
| Dec 31, 2023 | -44,000.00 |
| Dec 31, 2023 | -44,000.00 |
| Sep 30, 2023 | -88,000.00 |
| Sep 30, 2023 | -88,000.00 |
| Jun 30, 2023 | 118,000.00 |
| Jun 30, 2023 | 118,000.00 |